The metabolic syndrome is a complex and multifactorial disorder often associated with type 2 diabetes mellitus and cardiovascular diseases. The liver X receptor a (NR1H3) plays numerous roles in metabolic pathways involved in metabolic syndrome. Objective: In the search for susceptibility genes to metabolic syndrome, we hypothesized that common genetic variation in NR1H3 gene influences metabolic syndrome susceptibility. Design: Two large French population-based studies (n ¼ 1130 and 1160) including overall 664 individuals with and 1626 individuals without metabolic syndrome were genotyped for three polymorphisms (rs12221497, rs11039155 and rs2279239) of NR1H3. Results: We found that the À6A allele of rs11039155 was consistently associated with a 30% reduction in risk of metabolic syndrome in the two independent population samples (adjusted OR (95% CI) ¼ 0.68 (0.53-0.86), P ¼ 0.001 for the combined sample). Moreover, it was associated with an increase in plasma HDL-cholesterol concentrations (P ¼ 0.02 for the combined sample). Neither rs12221497 nor rs11039155, both polymorphisms located in the 5 0 region of NR1H3, had significant influence on NR1H3 and ATP-binding cassette transporter A1 (ABCA1) gene expression in primary human macrophages. Conclusions: These results suggest that NR1H3 plays an important role in the HDL-cholesterol metabolism and in the genetic susceptibility to metabolic syndrome.
Introduction
The concept of metabolic syndrome, according to the 2005 National Cholesterol Education Program (NCEP) III guidelines, 1 corresponds to the clustering of three among the five following factors in individuals: abdominal obesity, hyperglycemia, hypertriglyceridemia, hypoalphalipoproteinemia (low HDL-cholesterol levels) and arterial hypertension. Detecting individuals with a metabolic syndrome allows the discovery of individuals with a high risk of developing cardiovascular diseases. The metabolic syndrome is a complex and multifactorial disorder as its origin is due to the interaction between genetic susceptibility and environmental factors. Moreover, the metabolic pathways implicated in this syndrome are numerous and interact mutually. As an example, obesity favors dyslipidemia, insulin resistance and hypertension whereas insulin resistance often leads to gain weight. In our laboratory, we already identified several genetic susceptibility factors to metabolic syndrome 2,3 but many are still to discover. The identification of genes associated with metabolic syndrome is important to understand better the development of this disorder. Liver X receptor a (NR1H3, LXRA) is a nuclear receptor expressed in liver, spleen, kidney, adipose tissue, small intestine and macrophages 4 encoded by a gene located on 11p11.2. After its activation by cholesterol-derived oxysterols and heterodimerization with the retinoid X receptor, NR1H3 regulates the transcription of many target genes involved in cholesterol homeostasis, lipoprotein metabolism and lipogenesis. Among them, one can cite the genes encoding the ATP-binding cassette transporters and the apolipoprotein CI, CII, CIV and E, promoting the efflux and the reverse cholesterol transport. Genes encoding PLTP (phospholipid transfer protein) 5 and CETP (cholesterol ester transfer protein) 6 are also activated by NR1H3, which explains the role for NR1H3 in lipoprotein remodeling. Moreover, in liver, NR1H3 increases the expression of SREBP1c (sterol regulatory element binding protein 1c), FAS (fatty acid synthase) and PLTP, leading to de novo lipogenesis. Thus, NR1H3 plays numerous roles in metabolic pathways involved in metabolic syndrome and, therefore, it represents an excellent candidate gene for metabolic syndrome susceptibility. Little is known about the pathophysiological role of NR1H3 in humans. Although NR1H3 is not located in a susceptibility locus for the metabolic syndrome or related traits from genetic linkage analysis according to the 2005 Obesity Gene Map, 7 one study found significant association between a NR1H3 polymorphism and body mass index in Swedish women. 8 Therefore, we performed a large-scale association study of NR1H3 in two large French population-based studies (n ¼ 1130 and 1160).
Methods

Subjects
Participants were recruited in the framework of the WHO-MONICA population survey conducted from 1995 to 1997 in different regions of France: the Urban Community of Lille in the North (Lille, n ¼ 1195) and the Haute-Garonne county in the South (Toulouse, n ¼ 1182). The sample included individuals aged 35-65 years randomly selected on electoral rolls after stratification by town size, gender and age to obtain 200 participants for each gender and 10-year age group (WHO-MONICA Project protocol). 9, 10 The Ethical
Committee of each center approved the protocol. After signing an informed consent, participants were administered a standard questionnaire and physical measurements were made by a specially trained nurse. The level of physical activity during leisure time was categorized as: no physical activity, light (light physical activity almost every week), intense (at least 20 min of intense physical activity more than once a week). Current cigarette smokers were defined as individuals reporting at least one cigarette per day. Total alcohol intake was expressed as the sum of ml alcohol per week from wine, beer, cider and spirits. The anthropometric measurements included body weight (rounded to the nearest even decimal), waist (at a level midway between lower rib margin and iliac crest; to the nearest 0.5 cm) and were taken on individuals in light clothing without shoes. Body mass index was calculated according to the Quetelet equation.
Blood pressure was measured on the right arm, with the subject in a sitting position and after a minimum 5-min rest, using a standard mercury sphygmomanometer. 
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Laboratory methods A blood sample of 20 ml was drawn on disodium ethylenediaminetetraacetic acid after the subjects had fasted for at least 10 h. Lipid and lipoprotein levels were all measured in the Purpan Hospital Biochemical Laboratory (Toulouse). The quality of biological measures was assessed within the framework of the MONICA Project. Plasma glucose was measured by a standard glucose hexokinase method (DuPont Dimension, Brussels, Belgium). Plasma insulin was measured by radio-immunoassay (Medgenix Diagnostics, Brussels, Belgium). Plasma total cholesterol and triglyceride levels were measured by enzymatic methods (DuPont Dimension). Plasma high-density lipoprotein (HDL) cholesterol was measured after sodium phosphotungstate/magnesium chloride precipitation (Boehringer Mannheim, Mannheim, Germany). Plasma low-density lipoprotein cholesterol was calculated with the Friedewald equation.
DNA isolation and genotyping
Genomic DNA was extracted from white blood cells isolated from 20 ml of whole blood using a commercially available DNA isolation kit (DNA extraction kit; Stratagene, La Jolla, CA, USA). The typing of single nucleotide polymorphisms (SNPs) was done by the restriction fragment length polymorphism method (see Supplementary Information). Genotype data NR1H3 polymorphisms and metabolic syndrome V Legry et al were available for 1130 and 1160 subjects in the Lille and Toulouse population studies respectively. For each SNP, the PCR products had internal restriction sites (except for rs1449627) to avoid genotyping errors. Success rate was above 98% for all SNPs. All SNPs were in the Hardy-Weinberg equilibrium in the two population studies (all P40.05).
Pairwise linkage disequilibrium estimates were calculated using GOLD.
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Cell culture Human mononuclear cells were isolated from healthy blood donors by Ficoll density gradient centrifugation. Mature monocyte-derived macrophages were used after 10 days of culture in RPMI-1640 medium supplemented with 10% human serum.
RNA extraction and analysis
Total cellular RNA isolated from human macrophages treated or not for 24 h with the LXR ligand T0901317 (1 mmol/l) using Trizol (Invitrogen), was reverse-transcribed using random hexameric primers and multiscribe reverse transcriptase (Applied Biosystems). cDNAs were quantified by quantitative polymerase chain reaction (Q-PCR) on an MX4000 apparatus (Stratagene) using brilliant SYBR green (Stratagene) and specific primers: AGGGCTGCAAGG GATTCTTCC (forward), TCTGACAGCACACACTCCTCCC (reverse) for NR1H3, AAGGTCTTGTTCACCTCAGCCATGAC (forward), GTGAACAGCTCCAGCTCCTCCAC (reverse) for ABCA1 and GCATACGGGTCCTGGCATCTTGTCC (forward), ATGGTGATCTTCTTGCTGGTCTTGC (reverse) for cyclophilin. NR1H3 and ABCA1 mRNA levels were subsequently normalized to those of cyclophilin.
Statistical analysis
Statistical analyses were performed with the SAS statistical software, version 8 (SAS Institute Inc., Cary, NC, USA).
Statistical significance was considered when Pp0.05. Reported P-values are nominal. P-values for the comparison of the percentage of men (in Table 1 ) or genotypes (in Table 2 ) between subject groups were assessed using the w 
Results
NR1H3 SNPs were extracted from the NCBI dbSNP database. We selected 7 NR1H3 SNPs according to their minor allele frequency (above 8%) and potential functional consequence: rs12221497 (À115 G4A), rs11039155 (À6 G4A), rs2279239 (intron2 T4C), rs2279238 (exon3 C4T), rs7120118 (intron6 T4C), rs1449626 (intergenic region þ 512 A4C) and rs1449627 (intergenic region þ 737 T4G) (according to the NM_005693.1 sequence). To build the linkage disequilibrium map, a hundred individuals randomly selected from the MONICA Lille population were genotyped for these seven SNPs. The frequencies of the minor alleles were 13, 11, 27, 12, 26, 14 and 23% for the SNPs rs12221497, rs11039155, NR1H3 polymorphisms and metabolic syndrome V Legry et al rs2279239, rs2279238, rs7120118, rs1449626 and rs1449627, respectively. The linkage disequilibrium pattern across the SNPs was assessed using both D 0 and r 2 ( Figure 1 ). We identified two haplotype blocks in which three SNPs were in complete and perfect linkage disequilibrium (D 0 ¼ þ 1, 0.95pr 2 p1) (block 1: rs11039155, rs2279238 and rs1449626; block 2: rs2279239, rs7120118 and rs1449627). These results were in accordance with the HapMap database, at least for the three SNPs described in HapMap (rs12221497, rs2279238 and rs7120118). The SNP rs12221497 was not in complete linkage disequilibrium with the other SNPs (|D 0 | ¼ 1, r 2 o0.5) Therefore, we typed the three SNPs rs12221497, rs11039155 and rs2279239, in the MONICA Lille and Toulouse studies (n ¼ 1130 and 1160 respectively, comprising overall 664 individuals with metabolic syndrome) and assessed their impact on metabolic syndrome risk and related phenotypes. In MONICA Lille (n ¼ 1130), the frequencies of the NR1H3 rs12221497 (À115G4A), rs11039155 (À6G4A) and rs2279239 (intron2 T4C) minor alleles were 13.4, 12.8 and 27.1%, respectively. We compared the genotype distribution of these three polymorphisms between individuals with (n ¼ 363) and without (n ¼ 767) metabolic syndrome. The À115A allele frequency was higher in subjects with metabolic syndrome than in subjects without ( Table 2 ). The adjusted odds ratio (OR) (95% CI) of metabolic syndrome was 1.44 (1.07-1.94), P ¼ 0.02, for À115A allele bearers. Similarly, the adjusted OR (95% CI) of metabolic syndrome was 0.66 (0.48-0.91), P ¼ 0.01, for À6A allele bearers. No significant association could be detected between the intron2 T4C polymorphism and risk of metabolic syndrome.
In MONICA Toulouse (n ¼ 1160), the frequencies of the NR1H3 rs12221497 (À115G4A), rs11039155 (À6G4A) and rs2279239 (intron2 T4C) minor alleles were 12.3, 9.8 and 23.8%, respectively. There were 301 subjects with and 859 subjects without metabolic syndrome in this population sample. Neither the À115G4A polymorphism nor the intron2 T4C polymorphism was significantly associated with risk of metabolic syndrome (Table 2 ). In contrast, the À6G4A polymorphism was significantly associated with metabolic syndrome that is the adjusted OR of metabolic syndrome was 0.70 (0.48-1.00), P ¼ 0.05, for À6A allele bearers.
The ORs of metabolic syndrome for individuals carrying the À6A allele of the rs11039155 SNP were homogenous between the two population studies (Breslow -Day test P ¼ 0.83), allowing the pooling of the two samples. In the combined Lille and Toulouse population sample (664 subjects with and 1626 subjects without metabolic syndrome), the OR of metabolic syndrome for individuals carrying the À6A allele was 0.76 (0.60-0.95), P ¼ 0.02 (crude) and 0.68 (0.53-0.86), P ¼ 0.001, after adjustment for covariables. This association between the À6G4A polymorphism and risk of metabolic syndrome was homogenous in men and women: the adjusted OR of metabolic syndrome for individuals bearing the À6A allele was 0.67 (0.49-0.92), To understand the present association between the NR1H3 À6G4A SNP and the risk of metabolic syndrome, we evaluated the impact of this SNP on the clinical variables related to metabolic syndrome (that is, waist circumference, blood pressure, plasma glucose, triglyceride and HDLcholesterol levels) ( Table 3 ). We used combined whole Lille and Toulouse samples as they are population-based studies. We detected significant associations between the À6G4A polymorphism and plasma HDL-cholesterol concentrations; the À6A allele being associated with higher HDL-cholesterol levels (1.4770.45 vs 1.5370.48 mmol/l in GG vs GA þ AA subjects respectively, P ¼ 0.007 or P ¼ 0.02 after adjustment for age, gender, BMI, smoking habit, alcohol consumption, physical activity and center). This association was homogenous between population studies: 1.4870.46 vs 1.5570.50 mmol/l (adjusted P ¼ 0.15) and 1.4570.44 vs 1.5070.44 mmol/l (adjusted P ¼ 0.06) for GG vs GA þ AA subjects, in Lille and Toulouse studies respectively.
We also performed haplotype analyses with the three NR1H3 SNPs. We used the combined Lille and Toulouse sample to increase statistical power. Of the eight potential haplotypes defined by three SNPs, six inferred haplotypes were indeed observed in the sample.
Of these haplotypes, four occurred at frequencies 41% and accounted for 99.5% of the observed haplotypes. The frequencies for these four haplotypes are presented in Table 4 . The statistical analyses confirmed the importance of rs11039155 in metabolic syndrome. Indeed, the GAC haplotype (corresponding to the rs2221497, rs11039155 and rs2279239 SNPs in this order) was significantly associated with a decreased risk of metabolic syndrome (adjusted OR ¼ 0.73 (0.58-0.91), P ¼ 0.006) when compared to the GGT reference haplotype (Table 4) . No other haplotype was associated with metabolic syndrome risk.
To investigate a possible role of NR1H3 À6G4A and À115G4A polymorphisms on the expression of NR1H3 and ABCA1Fa target gene of NR1H3 involved in macrophage cholesterol efflux and HDL metabolismFQ-PCR analysis was performed on primary human macrophages treated or not with the LXR ligand T0901317 (1 mmol/l). NR1H3 expression level was not significantly different between genotype groups in the basal state ( Figure 2a ) and T0901317 activated NR1H3 expression similarly in all genotype groups (1.5-fold) (Figure 2b ). Moreover, ABCA1 gene expression was induced 10-fold by T0901317 in either subjects carrying the À115GG/À6GG genotypes or in carriers of the À115A allele, and 12-fold in carriers of the À6A allele (Figure 3 ) (ns).
Discussion
In this study, we found a consistent association between the NR1H3 À6A allele of rs11039155 and a lower risk of Table 3 Impact of the NR1H3 rs11039155 SNP on the biological variables associated with metabolic syndrome in the combined Lille and Toulouse population studies Data were log-transformed to obtain normal distributions. NR1H3 polymorphisms and metabolic syndrome V Legry et al metabolic syndrome in two independent population samples. Similar results were found when using the International Diabetes Federation criteria of metabolic syndrome (data not shown). Moreover, carriers of the À6A allele displayed higher plasma HDL-cholesterol concentrations compared with À6GG subjects. These results are in accordance with the physiological role of NR1H3. NR1H3 regulates many target genes involved in lipid uptake and efflux and lipoprotein metabolism.
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NR1H3 activators promote (i) the cellular transmembrane transport of endogenous lipid substrates via the induction of ABCA1, ABCG1, ABCG5, ABCG4, ABCG8 16, 17 in human macrophages and intestine; 18 (ii) the cholesterol trafficking from the endosome/lysosome to the plasma membrane through the activation of Niemann-Pick C (NPC) 1 and NPC2 expression in human macrophages; 19 (iii) the regulation of acceptors in cholesterol efflux such as ApoE, ApoCI, ApoCII and ApoCIV expression in adipocytes and macrophages 20 ; and (iv) the remodeling of lipoproteins through the control of modifying enzymes such as lipoprotein lipase (LPL) 21 and PLTP in liver and macrophages. 5 To support this, it has been shown that NR1H3 agonists raise plasma HDLcholesterol and triglyceride levels. 22 Therefore, NR1H3 plays a central role in many pathways involved in the onset of the metabolic syndrome, especially in HDL-cholesterol metabolism. It is worth noting that no significant association could NR1H3 polymorphisms and metabolic syndrome V Legry et al be detected between NR1H3 SNPs and plasma triglyceride concentrations in our study. Our results point towards the same direction than the study of Dahlman et al. 8 They showed that the CC genotype of SNP rs2279238 was associated with lower body mass index in Swedish women. In our population sample, rs2279238 was in perfect linkage disequilibrium with rs11039155, the SNP we found associated with a protective role against metabolic syndrome (D 0 ¼ þ 1, r 2 ¼ 0.95) whereas in Dahlman's study, it was not (D 0 ¼ þ 0.34, r 2 ¼ 0.11).
Both rs12221497 (À115G4A) and rs11039155 SNP (À6G4A), being located in the 5 0 region of NR1H3, could modify NR1H3 gene expression. We quantified NR1H3 mRNA levels in human primary macrophages but we did not detect any significant difference in NR1H3 expression level between genotype groups. Same results were obtained for ABCA1, a target gene of NR1H3 involved in cholesterol efflux in human macrophages which is associated with HDL-cholesterol levels in association studies. 23, 24 These data suggest that these polymorphisms do not modify NR1H3 or ABCA1 gene expression, at least in macrophages. Other cell types/tissues need to be tested. On the other hand, the À6G4A polymorphism is located six base pairs upstream from the ATG site, a position shown by Kozak to affect recognition of the AUG codon. The fact that the sequence flanking the AUG start codon in NR1H3 mRNA (GAAGA GATGT) does not closely match the Kozak consensus sequence (GACACCATGG) makes it more likely that the polymorphism might affect translational efficiency; that is a mutation in position À6 is more likely to have an effect in the absence of A in position À3 and G in position þ 4. 25 It would be therefore interesting to compare the level of NR1H3 protein produced in various tissues for example, liver, macrophages, adipose tissue between individuals with contrasted genotypes for the NR1H3 SNP rs11039155. On the other hand, it cannot be ruled out that another variant in linkage disequilibrium with the SNP rs11039155 may explain the present association.
In conclusion, we have assessed the role of common genetic variation in NR1H3 in susceptibility to metabolic syndrome. Among the different NR1H3 SNPs investigated, only the rs11039155 (À6G4A) polymorphism demonstrated consistent association with HDL-cholesterol levels and metabolic syndrome. The À6A allele was associated with an increase in HDL-cholesterol levels and a 30% reduction in the risk of metabolic syndrome. Other large populations of different countries are necessary to confirm this finding.
